Sweden's New Strategic Report Aims to Boost Clinical Trials Competitiveness
Sweden's new strategic report aims to enhance its competitiveness in clinical trials through national collaboration.
Key Points
- • Sweden aims to enhance its position in clinical trials through a strategic report.
- • National collaboration, defining clear roles, is essential for success.
- • Key regional and industry stakeholders are involved in the initiative.
- • The report suggests improved collaboration among healthcare providers and funding solutions.
A new report released on June 17, 2025, outlines Sweden's potential to enhance its position in the global market of clinical trials. The project, titled 'Stärkt svensk konkurrenskraft för kliniska prövningar', emphasizes the necessity of national collaboration among key regions and organizations. It highlights the collaborative effort of Region Skåne, Region Stockholm, Västra Götalandsregionen, as well as industry stakeholders such as Lif and SwedenBIO.
The report underscores that establishing clear roles and goals within this collaboration will be crucial to making Sweden a more attractive destination for clinical trials. Jesper Petersson, the research chief in Region Skåne, stated, "We have a strong will to further develop Swedish trial capacity, and the report clearly shows that a successful partnership is possible when we think collectively and long-term."
In addition to enhancing national cooperation, the report advocates for improved collaboration among healthcare providers, more transparent funding solutions, and supportive agreements to facilitate faster access to innovative treatments for patients. The findings were discussed in a concluding webinar, and materials detailing the data-driven decision support model have been made publicly available to support further exploration of this initiative.